Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 4,491 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer of Thorax Clear all

Conditions: Recurrent Pleural Malignant Mesothelioma, Stage IV Pleural Mesothelioma
Interventions: Nintedanib; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Detroit, Michigan • New York, New York

Conditions: Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
Interventions: [F-18]-5-FLUORO-2'-DEOXYCYTIDINE, Tetrahydrouridine intravenous (IV), Tetrahydrouridine (oral), Positron emission tomography (PET)/Computed tomography (CT); Drug · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-small Cell Lung Cancer
Interventions: MGY825; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 7
States / cities: Boston, Massachusetts • St Louis, Missouri • New York, New York + 1 more

Conditions: Metastatic Malignant Neoplasm in the Chest Wall, Recurrent Breast Carcinoma
Interventions: Olaparib, Hyperthermia Treatment, Questionnaire Administration, Quality-of-Life Assessment; Drug · Procedure · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lung Cancer
Interventions: EP-2101, incomplete Freund's adjuvant; Biological
Lead sponsor: Epimmune; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 9
States / cities: Ocoee, Florida • Albany, New York • Durham, North Carolina + 6 more

Conditions: Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
Interventions: erlotinib hydrochloride, therapeutic endoscopic surgery, laboratory biomarker analysis; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Small-cell Lung Cancer, Small Cell Lung Carcinoma
Interventions: Olaparib Pill 50 mg, Olaparib Pill 100 mg, Olaparib Pill 150 mg, Olaparib Pill 200 mg, Olaparib Pill 250 mg, Olaparib Pill 300 mg, Radiotherapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 9
States / cities: Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more

Conditions: Lung Cancer
Interventions: Vaccine Treatment, Cyclophosphamide, All-trans retinoic acid (ATRA); Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Lung Diseases, Cancer, Lung
Interventions: Spatial Frequency Domain Imaging; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Orange, California

Conditions: Colorectal Cancer, Dermatologic Complications, Lung Cancer, Therapy-related Toxicity
Interventions: assessment of therapy complications, psychosocial assessment and care, quality-of-life assessment; Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 113
States / cities: Tucson, Arizona • Castro Valley, California • Duarte, California + 78 more

Conditions: Lung Cancer, Breast Cancer, Gastrointestinal, Lymphomatous Malignancies
Interventions: Not listed
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Small Cell Lung Carcinoma
Interventions: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Etoposide, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 22
States / cities: Fort Myers, Florida • Orlando, Florida • St. Petersburg, Florida + 18 more

Conditions: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Interventions: Adagrasib, Pembrolizumab; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 220
States / cities: Goodyear, Arizona • Prescott Valley, Arizona • Safford, Arizona + 168 more

Conditions: Advanced Malignancies, Metastatic Cancer
Interventions: INCAGN01876, Nivolumab, Ipilimumab; Drug
Lead sponsor: Incyte Biosciences International Sàrl; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 15
States / cities: Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 12 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Temsirolimus, Radiation therapy; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Malignant Mesothelioma
Interventions: gemcitabine hydrochloride; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 84
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more

Conditions: Lung Carcinoma
Interventions: Iloprost, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 2
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Advanced Solid Tumors With and Without Brain Metastases
Interventions: ANG1005; Drug
Lead sponsor: Angiochem Inc; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Canton, Ohio • Houston, Texas • San Antonio, Texas

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: ABR-217620, docetaxel; Drug
Lead sponsor: Active Biotech AB; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non Small Cell Lung Cancer
Interventions: biospecimen collection; Other
Lead sponsor: Addario Lung Cancer Medical Institute; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions: Sacituzumab govitecan, Atezolizumab, Durvalumab; Drug
Lead sponsor: Bindu R Potugari; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Actinic Keratosis
Interventions: Ingenol mebutate gel, placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Carmel, Indiana

Conditions: Non-small Cell Lung Cancer
Interventions: bexarotene with carboplatin and paclitaxel, carboplatin and paclitaxel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: Not listed
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 121
States / cities: Montgomery, Alabama • Tucson, Arizona • Concord, California + 102 more

Conditions: Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Biliary Tract Cancer
Interventions: Ramucirumab, Pembrolizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 7
States / cities: New Haven, Connecticut • Fort Myers, Florida • St. Petersburg, Florida + 3 more

Search by objective public record fields.

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

Imaging Study for FdCyd and THU Cancer Treatment

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer

Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer

Analysis of Lung Cancer Tissue With Spatial Frequency Domain Imaging

S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride

DIBH Proton Planning

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Temsirolimus and Radiation for Non-Small Cell Lung Cancer

S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery

Iloprost in Preventing Lung Cancer in Former Smokers

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer

ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer

Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer